Extract from the Register of European Patents

EP About this file: EP1807091

EP1807091 - NOVEL USE OF LIGANDS SPECIFIC TO FEX-2 POLYPEPTIDE [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  25.09.2009
Database last updated on 11.04.2026
Most recent event   Tooltip25.09.2009Application deemed to be withdrawnpublished on 28.10.2009  [2009/44]
Applicant(s)For all designated states
Kyungpook National University Industry- Academic Cooperation Foundation
Kyungpook National University Sangyeok 3-dong, Book-gu
Daegu 702-701 / KR
[2007/29]
Inventor(s)01 / KIM, In-San
Dongseo Town, 106-908 Maeho-dong, Suseong-gu
Daegu 706-140 / KR
02 / PARK, Seung-Yoon
Cheongwoo Apt., 301-1912 Hwangseong-dong, Gyeongju
Gyeongbuk 780-761 / KR
03 / JUNG, Mi-Yeon
101, 46-1, Dongin 3-ga, Joong-gu
Daegu 700-423 / KR
04 / KIM, Ha-Jeong
Daedeok Mansion, 206-701 Bondeok 3-dong, Nam-gu
Daegu 705-023 / KR
 [2007/29]
Representative(s)Bockhorni & Brüntjen Partnerschaft Patentanwälte mbB
Agnes-Bernauer-Straße 88
80687 München / DE
[N/P]
Former [2008/31]Bockhorni & Kollegen
Elsenheimerstrasse 49
80687 München / DE
Former [2007/29]GROSSE BOCKHORNI SCHUMACHER
Patent- und Rechtsanwälte Elsenheimerstrasse 49
80687 München / DE
Application number, filing date05856534.212.10.2005
[2007/29]
WO2005KR03404
Priority number, dateKR2004008149912.10.2004         Original published format: KR 20040081499
[2007/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006080757
Date:03.08.2006
Language:EN
[2006/31]
Type: A1 Application with search report 
No.:EP1807091
Date:18.07.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 03.08.2006 takes the place of the publication of the European patent application.
[2007/29]
Search report(s)International search report - published on:KR03.08.2006
ClassificationIPC:A61K31/685, A61P37/06
[2007/29]
CPC:
A61K31/685 (EP,KR,US); A61K38/02 (KR); A61K39/395 (KR);
A61P1/04 (EP); A61P1/16 (EP); A61P1/18 (EP);
A61P11/00 (EP); A61P11/06 (EP); A61P17/00 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P19/06 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P27/02 (EP);
A61P27/16 (EP); A61P29/00 (EP); A61P29/02 (EP);
A61P3/06 (EP); A61P31/04 (EP); A61P35/00 (EP);
A61P37/06 (EP); A61P5/10 (EP); A61P5/18 (EP);
A61P7/00 (EP); A61P9/00 (EP); Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/29]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:NEUE VERWENDUNG VON FEX2-POLYPEPTID-SPEZIFISCHEN LIGANDEN[2007/29]
English:NOVEL USE OF LIGANDS SPECIFIC TO FEX-2 POLYPEPTIDE[2007/29]
French:NOUVELLE UTILISATION DE LIGANDS SPECIFIQUES AU POLYPEPTIDE FEX-2[2007/29]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase27.04.2007National basic fee paid 
27.04.2007Search fee paid 
27.04.2007Designation fee(s) paid 
27.04.2007Examination fee paid 
Examination procedure11.08.2006Request for preliminary examination filed
International Preliminary Examining Authority: KR
27.04.2007Examination requested  [2007/29]
05.07.2007Amendment by applicant (claims and/or description)
05.05.2009Application deemed to be withdrawn, date of legal effect  [2009/44]
15.06.2009Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2009/44]
Fees paidRenewal fee
29.10.2007Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.10.200804   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XP]   HOFFMANN ET AL.: "Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo", J. IMMUNOL., vol. 174, no. 3, February 2005 (2005-02-01), pages 1393 - 1404, XP003017529 [XP]
 [XP]   OTSUKA ET AL.: "Phosphatidylserine-specific receptor contributes to TGF-beta production in macrophages through a MAP kinase, ERK", BIOL. PHARM. BULL., vol. 28, no. 9, September 2005 (2005-09-01), pages 1707 - 1710, XP003017530 [XP]

DOI:   http://dx.doi.org/10.1248/bpb.28.1707
 [X]   GAIPL ET AL.: "Exposure of anionic phospholipids serve as anti-inflammatory and immunosuppresive signal implications for antiphospholipid syndrome and systemic lupus erythematosus", IMMUNOBIOLOGY, vol. 207, no. 1, 2003, pages 73 - 81, XP009009808 [X]

DOI:   http://dx.doi.org/10.1078/0171-2985-00217
 [X]   HUYNH ET AL.: "Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation", J. CLIN. INVEST., vol. 109, no. 1, 2002, pages 41 - 50, XP003017531 [X]

DOI:   http://dx.doi.org/10.1172/JCI200211638
 [X]   MATSUNO ET AL: "Involvement of TGF-beta in inhibitory effects of negatively charged liposomes on nitric oxide production by macrophages stimulated with LPS", BIOCHEM. BIOPHYS. RES. COMM., vol. 281, no. 3, 2001, pages 614 - 620, XP003017532 [X]

DOI:   http://dx.doi.org/10.1006/bbrc.2001.4419
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.